Xiaoyu Li - Anpac Bio CFO Director
| ANPCDelisted Stock | USD 4.37 0.20 4.38% |
Insider
Xiaoyu Li is CFO Director of Anpac Bio Medical
| Age | 34 |
| Phone | 86 57 8205 1666 |
| Web | https://www.anpacbio.com |
Xiaoyu Li Latest Insider Activity
Tracking and analyzing the buying and selling activities of Xiaoyu Li against Anpac Bio stock is an integral part of due diligence when investing in Anpac Bio. Xiaoyu Li insider activity provides valuable insight into whether Anpac Bio is net buyers or sellers over its current business cycle. Note, Anpac Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Anpac Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Xiaoyu Li a day ago Disposition of 471695 shares by Xiaoyu Li of Fresh2 subject to Rule 16b-3 | ||
Xiaoyu Li 2 days ago Disposition of 471695 shares by Xiaoyu Li of Fresh2 subject to Rule 16b-3 | ||
Xiaoyu Li 3 days ago Disposition of 471695 shares by Xiaoyu Li of Fresh2 subject to Rule 16b-3 | ||
Xiaoyu Li few days ago Disposition of 471695 shares by Xiaoyu Li of Fresh2 subject to Rule 16b-3 |
Anpac Bio Management Efficiency
The company has return on total asset (ROA) of (0.5264) % which means that it has lost $0.5264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4312) %, meaning that it created substantial loss on money invested by shareholders. Anpac Bio's management efficiency ratios could be used to measure how well Anpac Bio manages its routine affairs as well as how well it operates its assets and liabilities.Anpac Bio Medical currently holds 19.81 M in liabilities with Debt to Equity (D/E) ratio of 1.44, which is about average as compared to similar companies. Anpac Bio Medical has a current ratio of 0.38, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Anpac Bio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| MD BA | Lumos Pharma | 69 | |
| Mythili MD | Marker Therapeutics | 46 | |
| Igor MD | Celcuity LLC | N/A | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Deepika PharmD | Pmv Pharmaceuticals | 48 | |
| Paul MD | AN2 Therapeutics | 54 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Randi MD | Werewolf Therapeutics | 68 | |
| MBA BS | AN2 Therapeutics | 49 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Timothy CPA | Werewolf Therapeutics | 66 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Sarah Longoria | Exicure | 42 | |
| Lori CPA | Lumos Pharma | 40 | |
Management Performance
| Return On Equity | -2.43 | |||
| Return On Asset | -0.53 |
Anpac Bio Medical Leadership Team
Elected by the shareholders, the Anpac Bio's board of directors comprises two types of representatives: Anpac Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anpac. The board's role is to monitor Anpac Bio's management team and ensure that shareholders' interests are well served. Anpac Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anpac Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sunil Pandit, US Officer | ||
| Xiaoyu Li, CFO Director | ||
| Weidong Dai, China Pres | ||
| Haohan Xu, CoCEO CoChairperson | ||
| He Yu, CoFounder Officer | ||
| Chris Yu, CoCEO CoFounder |
Anpac Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anpac Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.43 | |||
| Return On Asset | -0.53 | |||
| Operating Margin | (8.71) % | |||
| Current Valuation | 9.28 M | |||
| Shares Outstanding | 6.27 M | |||
| Shares Owned By Insiders | 2.15 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Number Of Shares Shorted | 44.48 K | |||
| Price To Book | 5.67 X | |||
| Price To Sales | 0.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Anpac Stock
If you are still planning to invest in Anpac Bio Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anpac Bio's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |